PT  - JOURNAL ARTICLE
AU  - Javier Perez-Saez
AU  - María-Eugenia Zaballa
AU  - Sabine Yerly
AU  - Diego O. Andrey
AU  - Benjamin Meyer
AU  - Isabella Eckerle
AU  - Jean-François Balavoine
AU  - François Chappuis
AU  - Didier Pittet
AU  - Didier Trono
AU  - Omar Kherad
AU  - Nicolas Vuilleumier
AU  - Laurent Kaiser
AU  - Idris Guessous
AU  - Silvia Stringhini
AU  - Andrew S Azman
AU  - for the Specchio-COVID19 Study Group
TI  - Persistence and detection of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance
AID  - 10.1101/2021.03.16.21253710
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.16.21253710
4099  - http://medrxiv.org/content/early/2021/03/20/2021.03.16.21253710.short
4100  - http://medrxiv.org/content/early/2021/03/20/2021.03.16.21253710.full
AB  - Serologic studies have been critical in tracking the evolution of the COVID-19 pandemic. The reliability of serologic studies for quantifying the proportion of the population that have been infected depends on the extent of antibody decay as well as on assay performance in detecting both recent and older infections. Data on anti-SARS-CoV-2 antibodies persistence remain sparse, especially from infected individuals with few to no symptoms. In a cohort of mostly mild/asymptomatic SARS-CoV-2-infected individuals tested with three widely-used immunoassays, antibodies persisted for at least 8 months after infection, although detection depended on immunoassay choice, with one of them missing up to 40% of past infections. Simulations reveal that without appropriate adjustment for time-varying assay sensitivity, seroprevalence surveys may underestimate infection rates. As the immune landscape becomes more complex with naturally-infected and vaccinated individuals, assay choice and appropriate assay-performance-adjustment will become even more important for the interpretation of serologic studies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Private Foundation of the Geneva University Hospitals, the General Directorate of Health of the Department of Safety, Employment and Health of the canton of Geneva, the Swiss Federal Office of Public Health, the Fondation des Grangettes and the Center for Emerging Viral Diseases. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:is study was approved by the Geneva Cantonal Commission for Research Ethics (CCER project number 2020-00881).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode are available at https://github.com/UEP-HUG/serosuivi-public along with dummy data. Data can be made available upon request by contacting the corresponding author. https://github.com/UEP-HUG/serosuivi-public